View More Recent Stories

Mar 4, 2022 07:30AM Adamis Pharmaceuticals Announces Retirement of Richard C. Williams, Chairman of the Board
Feb 28, 2022 07:31AM Adamis Pharmaceuticals (ADMP) Says Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
Feb 28, 2022 07:30AM Adamis Pharmaceuticals’ Clinical Study Assessing Tempol for the Treatment of COVID-19 Surpasses Enrollment Expectations
Feb 18, 2022 04:05PM Adamis Announces Inducement Option Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 7, 2022 09:18AM Adamis Pharmaceuticals (ADMP) Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol
Feb 7, 2022 09:17AM Adamis Pharmaceuticals Provides Enrollment Update of Subjects in Phase 2/3 Study of Tempol for the Treatment of COVID-19
Jan 10, 2022 07:34AM Adamis Pharmaceuticals (ADMP) Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
Jan 10, 2022 07:30AM Adamis Pharmaceuticals Submits Fast Track Application to FDA for Tempol for the Treatment and Prevention of COVID-19
Dec 1, 2021 07:33AM Adamis Pharmaceuticals (ADMP) Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI
Dec 1, 2021 07:30AM Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
Nov 23, 2021 02:40PM Adamis Pharmaceuticals (ADMP) Regains Compliance with NASDAQ Continued Listing Requirements
Nov 23, 2021 02:39PM Adamis Pharmaceuticals Regains Compliance with NASDAQ Continued Listing Requirements
Nov 22, 2021 04:47PM Adamis Pharmaceuticals Announces Third Quarter 2021 Financial Results and Provides Corporate Update
Nov 19, 2021 03:34PM Adamis Pharmaceuticals Schedules Financial Results Conference Call and Business Update
View More Recent Stories